Chat with us
Research Assistance
Online
  • Please enter your first name.

Mexico - Latin America Influenza Vaccine Market Size & Outlook

The influenza vaccine market in Mexico - Latin America is expected to reach a projected revenue of US$ 85.4 million by 2030. A compound annual growth rate of 7.8% is expected of Mexico - Latin America influenza vaccine market from 2024 to 2030.

  • Pharmaceuticals
    • Vaccines
      • Influenza Vaccine Market Outlook
Revenue, 2023 (US$M)
$50.9
Forecast, 2030 (US$M)
$85.4
CAGR, 2024 - 2030
7.8%
Report Coverage
Mexico
Mexico - Latin America Influenza Vaccine Market, 2018-2030 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Prism AI by Grand View ResearchFree to try

Ask a question about the influenza vaccine market

Every figure cited from GVR research

Mexico influenza vaccine market highlights

  • The Mexico influenza vaccine market generated a revenue of USD 50.9 million in 2023 and is expected to reach USD 85.4 million by 2030.
  • The Mexico market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
  • In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
  • Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.


Influenza vaccine market data book summary

Market revenue in 2023USD 50.9 million
Market revenue in 2030USD 85.4 million
Growth rate7.8% (CAGR from 2024 to 2030)
Largest segmentInactivated
Fastest growing segmentInactivated
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationInactivated, Live Attenuated
Key market players worldwideGSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines


Other key industry trends

  • In terms of revenue, Mexico accounted for 0.6% of the global influenza vaccine market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
  • Argentina is the fastest growing regional market in Latin America and is projected to reach USD 43.5 million by 2030.

Mexico has a high rate of infectious diseases coupled with the growth of the country's biotechnology & biopharmaceutical industries, owing to the increasing number of startups and rising investments. These factors are expected to contribute to the market growth.

Some of the key players in Mexico are Pfizer, Inc., GSK plc, Sanofi, and others. In addition, several government initiatives to promote influenza vaccine uptake are also expected to push the market forward.

For instance, in September 2022, the government of Mexico initiated influenza vaccination campaign to manage the flu burden of the country. Moreover, in November 2022, Mexico initiated vaccination in birds to combat the spread of contagious H5N1 strain of bird flu in the country.

No credit card required*

Publish Date: Dec 15, 2025

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Influenza Vaccine Market Companies

NameProfile# EmployeesHQWebsite
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Merck & Co IncView profile 72,000126 East Lincoln Avenue, Rahway, NJ, United States, 07065www.merck.com
GSK PLCView profile 70,200980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GSwww.gsk.com
AstraZeneca PLCView profile 89,9001 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AAwww.astrazeneca.com
Viatris IncView profile 38,0001000 Mylan Boulevard, Canonsburg, PA, United States, 15317www.viatris.com
Sinovac Biotech LtdView profile 3,261No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085www.sinovac.com
CSL LtdView profile 32,000655 Elizabeth Street, Melbourne, VIC, Australia, 3000www.csl.com
Emergent BioSolutions IncView profile 1,600300 Professional Drive, Gaithersburg, MD, United States, 20879www.emergentbiosolutions.com
Vaxess TechnologiesView profile 51-100Cambridge, Massachusetts, United States, North Americawww.vaxess.com
OsivaxView profile 11-50Lyon, Rhone-Alpes, France, Europewww.osivax.com/

Mexico - Latin America Influenza Vaccine Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.


Inactivated was the largest segment with a revenue share of 99.21% in 2023.

Horizon Databook has segmented the Mexico - Latin America influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.




Mexico has a high rate of infectious diseases coupled with the growth of the country's biotechnology & biopharmaceutical industries, owing to the increasing number of startups and rising investments. These factors are expected to contribute to the market growth.

Some of the key players in Mexico are Pfizer, Inc., GSK plc, Sanofi, and others. In addition, several government initiatives to promote influenza vaccine uptake are also expected to push the market forward.

For instance, in September 2022, the government of Mexico initiated influenza vaccination campaign to manage the flu burden of the country. Moreover, in November 2022, Mexico initiated vaccination in birds to combat the spread of contagious H5N1 strain of bird flu in the country.

  • Mexico - Latin America Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
    • Inactivated
    • Live Attenuated
  • Mexico - Latin America Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
    • Quadrivalent
    • Trivalent
  • Mexico - Latin America Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
    • Pediatric
    • Adult
  • Mexico - Latin America Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
    • Injection
    • Nasal Spray
  • Mexico - Latin America Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
    • Hospitals & Pharmacy
    • Government & Institutional supply
    • Other Distribution Channels

Reasons to subscribe to Influenza Vaccine Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Influenza Vaccine Market Outlook databook

  • Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Mexico - Latin America Influenza Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Mexico - Latin America Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Mexico - Latin America Influenza Vaccine Market, 2018-2030 (US$M)

No Access Stack Chart

Mexico influenza vaccine market statistics, by vaccine type, 2018-2030 (US$M)

No Access Pie Chart

Mexico influenza vaccine market statistics, by vaccine type, 2018-2030 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more